Central Nervous System Involvement in Pediatric Systemic Autoimmune Diseases

Abstract

Central nervous system (CNS) involvement occurs in many pediatric systemic autoimmune diseases. These manifestations are often associated with increased morbidity and mortality and can have adverse long-term effects on neurodevelopmental, health-related, and quality-of-life outcomes. In this review, we summarize the existing literature on CNS involvement in pediatric systemic autoimmune diseases, compare diagnostic findings, and describe current treatments. CNS manifestations of pediatric systemic autoimmune disease present diagnostic and management challenges due to their relatively rare occurrence in children, the difficulty in confirming direct CNS involvement as opposed to secondary symptoms occurring as a consequence of systemic inflammation, and the need to define treatment strategies effective for CNS involvement.

Keywords

systemic autoimmune disease - pediatric - central nervous system

• References

• 1 Sacks JJ, Helmick CG, Luo YH, Ilowite NT, Bowyer S. Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001–2004. Arthritis Rheum 2007; 57 (08) 1439-1445
• 2 Developing Adolescents. A Reference for Professionals. Washington, DC: American Psychological Association; 2002
• 3 Duzova A, Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment. Curr Pharm Des 2008; 14 (13) 1295-1301
• 4 Cassidy JTPR, Laxer RM, Lindsley CB. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2005
• 5 Uziel Y, Brik R, Padeh S. , et al; The Pediatric Rheumatology Study Group of Israel Juvenile Behçet's disease in Israel. Clin Exp Rheumatol 1998; 16 (04) 502-505
• 6 Hoffman IE, Lauwerys BR, De Keyser F. , et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009; 68 (03) 412-415
• 7 Bernstein CM, Stockwell MS, Gallagher MP, Rosenthal SL, Soren K. Mental health issues in adolescents and young adults with type 1 diabetes: prevalence and impact on glycemic control. Clin Pediatr (Phila) 2013; 52 (01) 10-15
• 8 Reigada LC, Bruzzese JM, Benkov KJ. , et al. Illness-specific anxiety: implications for functioning and utilization of medical services in adolescents with inflammatory bowel disease. J Spec Pediatr Nurs 2011; 16 (03) 207-215
• 9 Calsbeek H, Rijken M, Bekkers MJ, Dekker J, van Berge Henegouwen GP. School and leisure activities in adolescents and young adults with chronic digestive disorders: impact of burden of disease. Int J Behav Med 2006; 13 (02) 121-130
• 10 Cassidy JT. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia, PA: Saunders/Elsevier; 2011
• 11 ACR Ad Hoc Committee on Neuropsychiatric Lupus Syndromes. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42 (04) 599-608
• 12 Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007; 16 (08) 564-571
• 13 Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014; 10 (06) 338-347
• 14 Schor NF. Neurology of systemic autoimmune disorders: a pediatric perspective. Semin Pediatr Neurol 2000; 7 (02) 108-117
• 15 Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012; 27 (08) 935-946
• 16 Lim LS, Lefebvre A, Benseler S, Peralta M, Silverman ED. Psychiatric illness of systemic lupus erythematosus in childhood: spectrum of clinically important manifestations. J Rheumatol 2013; 40 (04) 506-512
• 17 Colasanti T, Delunardo F, Margutti P. , et al. Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J Neuroimmunol 2009; 212 (1–2): 3-9
• 18 Swaiman K, Ashwal S, Ferriero DM. Pediatric Neurology: Principles and Practice. Vol 1–2. 4th ed. Philadelphia, PA: Mosby Elsevier; 2006
• 19 Kashihara K, Nakashima S, Kohira I, Shohmori T, Fujiwara Y, Kuroda S. Hyperintense basal ganglia on T1-weighted MR images in a patient with central nervous system lupus and chorea. Am J Neuroradiol 1998; 19 (02) 284-286
• 20 McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995; 58 (05) 548-554
• 21 Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 1981; 70 (02) 240-246
• 22 Yoshio T, Hirata D, Onda K, Nara H, Minota S. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005; 32 (01) 34-39
• 23 Lim LS, Lefebvre A, Benseler S, Silverman ED. Long-term outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction. J Rheumatol 2013; 40 (04) 513-519
• 24 Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 1979; 8 (03) 212-221
• 25 Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19 (05) 732-741
• 26 Baca V, Lavalle C, García R. , et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26 (02) 432-439
• 27 Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98 (01) 32-41
• 28 Dale RC, Brilot F, Duffy LV. , et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014; 83 (02) 142-150
• 29 Hashimoto H, Yano T, Kawanishi T, Tsuda H, Nagasawa T. Outcome of collagen vascular diseases by treatment with plasmapheresis. Ther Apher 1998; 2 (04) 268-272
• 30 Valencia I. Epilepsy in systemic autoimmune disorders. Semin Pediatr Neurol 2014; 21 (03) 226-231
• 31 Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981; 24 (11) 1389-1395
• 32 Steinlin MI, Blaser SI, Gilday DL. , et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol 1995; 13 (03) 191-197
• 33 Burch JM, Lee LA, Weston WL. Neonatal lupus erythematosus. Dermatol Nurs 2002; 14 (03) 157-160
• 34 Chen CC, Lin KL, Chen CL, Wong AM, Huang JL. Central nervous system manifestations of neonatal lupus: a systematic review. Lupus 2013; 22 (14) 1484-1488
• 35 Boros CA, Spence D, Blaser S, Silverman ED. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57 (02) 261-266
• 36 Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 2002; 81 (01) 203-206
• 37 Dörner T, Feist E, Pruss A, Chaoui R, Göldner B, Hiepe F. Significance of autoantibodies in neonatal lupus erythematosus. Int Arch Allergy Immunol 2000; 123 (01) 58-66
• 38 Prendiville JS, Cabral DA, Poskitt KJ, Au S, Sargent MA. Central nervous system involvement in neonatal lupus erythematosus. Pediatr Dermatol 2003; 20 (01) 60-67
• 39 Inoue K, Fukushige J, Ohno T, Igarashi H, Hara T. Central nervous system vasculopathy associated with neonatal lupus. Pediatr Neurol 2002; 26 (01) 68-70
• 40 Zuppa AA, Gallini F, De Luca D. , et al. Cerebral ultrasound findings in neonatal lupus syndrome. Biol Neonate 2004; 86 (04) 230-234
• 41 Aguiar CL, Soybilgic A, Avcin T, Myones BL. Pediatric antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17 (04) 27
• 42 Avcin T, Cimaz R, Silverman ED. , et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008; 122 (05) e1100-e1107
• 43 Sibbitt Jr WL, Brandt JR, Johnson CR. , et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29 (07) 1536-1542
• 44 Levy DM, Massicotte MP, Harvey E, Hebert D, Silverman ED. Thromboembolism in paediatric lupus patients. Lupus 2003; 12 (10) 741-746
• 45 Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus 2010; 19 (04) 406-411
• 46 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
• 47 Berman H, Rodríguez-Pintó I, Cervera R. , et al; Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev 2014; 13 (02) 157-162
• 48 Aziz A, Conway MD, Robertson HJ, Espinoza LR, Wilson WA. Acute optic neuropathy and transverse myelopathy in patients with antiphospholipid antibody syndrome: favorable outcome after treatment with anticoagulants and glucocorticoids. Lupus 2000; 9 (04) 307-310
• 49 Patterson SL, LaMonte MP, Mikdashi JA, Haines ST, Hursting MJ. Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature. Pharmacotherapy 2006; 26 (10) 1518-1525
• 50 Pons I, Espinosa G, Cervera R. Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review [in Spanish]. Med Clin (Barc) 2015; 144 (03) 97-104
• 51 Sciascia S, Khamashta MA, D'Cruz DP. Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 2014; 26 (03) 269-275
• 52 Niemelä RK, Hakala M. Primary Sjögren's syndrome with severe central nervous system disease. Semin Arthritis Rheum 1999; 29 (01) 4-13
• 53 Ioannidis JP, Moutsopoulos HM. Sjögren's syndrome: too many associations, too limited evidence. The enigmatic example of CNS involvement. Semin Arthritis Rheum 1999; 29 (01) 1-3
• 54 Rojas-Rodriguez J, Garcia-Carrasco M, Ramirez ES. , et al. Optic neuropathy in a child with primary Sjögren's syndrome. Rev Rhum Engl Ed 1998; 65 (05) 355-357
• 55 Gerraty RP, McKelvie PA, Byrne E. Aseptic meningoencephalitis in primary Sjögren's syndrome. Response to plasmapheresis and absence of CNS vasculitis at autopsy. Acta Neurol Scand 1993; 88 (04) 309-311
• 56 Nagahiro S, Mantani A, Yamada K, Ushio Y. Multiple cerebral arterial occlusions in a young patient with Sjögren's syndrome: case report. Neurosurgery 1996; 38 (03) 592-595 , discussion 595
• 57 Matsui Y, Takenouchi T, Narabayashi A, Ohara K, Nakahara T, Takahashi T. Childhood Sjögren syndrome presenting as acute brainstem encephalitis. Brain Dev 2016; 38 (01) 158-162
• 58 Derle E, Güneş HN, Konuşkan B, Tuncer-Kurne A. Neuromyelitis optica in children: a review of the literature. Turk J Pediatr 2014; 56 (06) 573-580
• 59 Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993; 19 (04) 869-908
• 60 Gottfried JA, Finkel TH, Hunter JV, Carpentieri DF, Finkel RS. Central nervous system Sjögren's syndrome in a child: case report and review of the literature. J Child Neurol 2001; 16 (09) 683-685
• 61 Delalande S, de Seze J, Fauchais AL. , et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83 (05) 280-291
• 62 Williams CS, Butler E, Román GC. Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001; 58 (05) 815-819
• 63 Fukuda T, Shiraishi H, Nakamura T. , et al. Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies. J Neurol 2009; 256 (10) 1762-1764
• 64 Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin. Neurology 2003; 60 (03) 503-505
• 65 Zulian F, Vallongo C, Woo P. , et al; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52 (09) 2873-2881
• 66 Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am 2008; 34 (01) 239-255 , ix ix
• 67 Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol 2012; 29 (06) 738-748
• 68 Estey E, Lieberman A, Pinto R, Meltzer M, Ransohoff J. Cerebral arteritis in scleroderma. Stroke 1979; 10 (05) 595-597
• 69 Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70 (11) 1068-1076
• 70 Zulian F, Woo P, Athreya BH. , et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007; 57 (02) 203-212
• 71 Holland KE, Steffes B, Nocton JJ, Schwabe MJ, Jacobson RD, Drolet BA. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006; 117 (01) e132-e136
• 72 Lee YJ, Chung KY, Kang HC, Kim HD, Lee JS. Parry-Romberg syndrome with ipsilateral hemipons involvement presenting as monoplegic ataxia. Korean J Pediatr 2015; 58 (09) 354-357
• 73 Li SC, Torok KS, Pope E. , et al; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) 2012; 64 (08) 1175-1185
• 74 Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 2013; 43 (03) 335-347
• 75 James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976; 278: 321-334
• 76 James DG. Epidemiology and management of sarcoidosis. Practitioner 1969; 202 (211) 624-631
• 77 Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43 (01) 8-12
• 78 Baumann RJ, Robertson Jr WC. Neurosarcoid presents differently in children than in adults. Pediatrics 2003; 112 (6 Pt 1): e480-e486
• 79 Weinberg S, Bennett H, Weinstock I. Central nervous system manifestations of sarcoidosis in children. Case report and review. Clin Pediatr (Phila) 1983; 22 (07) 477-481
• 80 Day AL, Sypert GW. Spinal cord sarcoidosis. Ann Neurol 1977; 1 (01) 79-85
• 81 Caroscio JT, Yahr MD. Progressive myelopathy due to sarcoid. Clin Neurol Neurosurg 1980; 82 (04) 217-222
• 82 Jallo GI, Zagzag D, Lee M, Deletis V, Morota N, Epstein FJ. Intraspinal sarcoidosis: diagnosis and management. Surg Neurol 1997; 48 (05) 514-520 , discussion 521
• 83 Keesling CA, Frush DP, O'Hara SM, Fordham LA. Clinical and imaging manifestations of pediatric sarcoidosis. Acad Radiol 1998; 5 (02) 122-132
• 84 Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol 2015; 285: 1-3
• 85 Khoury J, Wellik KE, Demaerschalk BM, Wingerchuk DM. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist 2009; 15 (02) 108-111
• 86 Gedalia A, Molina JF, Ellis Jr GS, Galen W, Moore C, Espinoza LR. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997; 130 (01) 25-29
• 87 Hayes WS, Sherman JL, Stern BJ, Citrin CM, Pulaski PDMR. MR and CT evaluation of intracranial sarcoidosis. Am J Roentgenol 1987; 149 (05) 1043-1049
• 88 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155 (08) 846-851
• 89 Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 2007; 64 (05) 691-696
• 90 O'Dwyer JP, Al-Moyeed BA, Farrell MA. , et al. Neurosarcoidosis-related intracranial haemorrhage: three new cases and a systematic review of the literature. Eur J Neurol 2013; 20 (01) 71-78
• 91 Lorentzen AO, Sveberg L, Midtvedt Ø, Kerty E, Heuser K. Overnight response to infliximab in neurosarcoidosis: a case report and review of infliximab treatment practice. Clin Neuropharmacol 2014; 37 (05) 142-148
• 92 Fuchigami T, Inamo Y, Hashimoto K. , et al. Henoch–Schönlein purpura complicated by reversible posterior leukoencephalopathy syndrome. Pediatr Emerg Care 2010; 26 (08) 583-585
• 93 Belman AL, Leicher CR, Moshé SL, Mezey AP. Neurologic manifestations of Schoenlein–Henoch purpura: report of three cases and review of the literature. Pediatrics 1985; 75 (04) 687-692
• 94 Ritter FJ, Seay AR, Lahey ME. Peripheral mononeuropathy complicating anaphylactoid purpura. J Pediatr 1983; 103 (01) 77-78
• 95 Chen CL, Chiou YH, Wu CY, Lai PH, Chung HM. Cerebral vasculitis in Henoch–Schönlein purpura: a case report with sequential magnetic resonance imaging changes and treated with plasmapheresis alone. Pediatr Nephrol 2000; 15 (3–4): 276-278
• 96 Ostergaard JR, Storm K. Neurologic manifestations of Schönlein–Henoch purpura. Acta Paediatr Scand 1991; 80 (03) 339-342
• 97 Bérubé MD, Blais N, Lanthier S. Neurologic manifestations of Henoch–Schönlein purpura. Handb Clin Neurol 2014; 120: 1101-1111
• 98 Ozen S, Pistorio A, Iusan SM. , et al; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69 (05) 798-806
• 99 Wen YK, Yang Y, Chang CC. Cerebral vasculitis and intracerebral hemorrhage in Henoch–Schönlein purpura treated with plasmapheresis. Pediatr Nephrol 2005; 20 (02) 223-225
• 100 Shin JI, Lee JS, Kim HD, Lee JS, Lee YM. Neurologic manifestations and treatment of Henoch–Schönlein purpura. Brain Dev 2006; 28 (08) 547
• 101 Bulun A, Topaloglu R, Duzova A, Saatci I, Besbas N, Bakkaloglu A. Ataxia and peripheral neuropathy: rare manifestations in Henoch–Schönlein purpura. Pediatr Nephrol 2001; 16 (12) 1139-1141
• 102 Altinörs N, Cepoğlu C. Surgically treated intracerebral hematoma in a child with Henoch–Schönlein purpura. J Neurosurg Sci 1991; 35 (01) 47-49
• 103 Bakkaloğlu SA, Ekim M, Tümer N, Deda G, Erden I, Erdem T. Cerebral vasculitis in Henoch–Schönlein purpura. Nephrol Dial Transplant 2000; 15 (02) 246-248
• 104 Perez C, Maravi E, Olier J, Guarch R. MR imaging of encephalopathy in adult Henoch–Shönlein purpura. Am J Roentgenol 2000; 175 (03) 922-923
• 105 Miyazawa T, Sugimoto K, Fujita S. , et al. A patient with Henoch–Schönlein purpura manifesting unusual symptoms and clinical course. J Clin Rheumatol 2010; 16 (07) 338-340
• 106 Dengler LD, Capparelli EV, Bastian JF. , et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J 1998; 17 (06) 478-481
• 107 Tabarki B, Mahdhaoui A, Selmi H, Yacoub M, Essoussi AS. Kawasaki disease with predominant central nervous system involvement. Pediatr Neurol 2001; 25 (03) 239-241
• 108 Larralde M, Santos-Muñoz A, Rutiman R. Kawasaki disease with facial nerve paralysis. Pediatr Dermatol 2003; 20 (06) 511-513
• 109 Dajani AS, Taubert KA, Gerber MA. , et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87 (05) 1776-1780
• 110 Hikita T, Kaminaga T, Wakita S. , et al. Regional cerebral blood flow abnormalities in patients with Kawasaki disease. Clin Nucl Med 2011; 36 (08) 643-649
• 111 Novo A, Pinto S, Prior AC, Alvares S, Soares T, Guedes M. Kawasaki disease and sensorineural hearing loss: an (un)expected complication. Eur J Pediatr 2012; 171 (05) 851-854
• 112 Itamura S, Kamada M, Nakagawa N. Kawasaki disease complicated with reversible splenial lesion and acute myocarditis. Pediatr Cardiol 2011; 32 (05) 696-699
• 113 Geevarghese B, Gaensbauer J, Cataldi J, Schultz M, Asturias EJ, Dominguez SR. Acute demyelinating lesion of the upper thoracic spine complicating Kawasaki disease. J Pediatric Infect Dis Soc 2013; 2 (04) 397-401
• 114 Husain E, Hoque E. Meningoencephalitis as a presentation of Kawasaki disease. J Child Neurol 2006; 21 (12) 1080-1081
• 115 Koné-Paut I, Yurdakul S, Bahabri SA. , et al. Clinical features of Behçet's disease in children: an international collaborative study of 86 cases. J Pediatr 1998; 132 (04) 721-725
• 116 Fujikawa S, Suemitsu T. Behçet disease in children: a nationwide retrospective survey in Japan. Acta Paediatr Jpn 1997; 39 (02) 285-289
• 117 Uluduz D, Kürtüncü M, Yapıcı Z. , et al. Clinical characteristics of pediatric-onset neuro-Behçet disease. Neurology 2011; 77 (21) 1900-1905
• 118 Koné-Paut I, Chabrol B, Riss JM, Mancini J, Raybaud C, Garnier JM. Neurologic onset of Behçet's disease: a diagnostic enigma in childhood. J Child Neurol 1997; 12 (04) 237-241
• 119 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335 (8697): 1078-1080
• 120 Nobili F, Cutolo M, Sulli A, Vitali P, Vignola S, Rodriguez G. Brain functional involvement by perfusion SPECT in systemic sclerosis and Behçet's disease. Ann N Y Acad Sci 2002; 966: 409-414
• 121 Alkan A, Goktan A, Karincaoglu Y. , et al. Brain perfusion MRI findings in patients with . Behçet's disease. Sci World J 2012; 2012: 261502
• 122 Hirohata S. Histopathology of central nervous system lesions in Behçet's disease. J Neurol Sci 2008; 267 (1–2): 41-47
• 123 Rakover Y, Adar H, Tal I, Lang Y, Kedar A. Behçet disease: long-term follow-up of three children and review of the literature. Pediatrics 1989; 83 (06) 986-992
• 124 Budin C, Ranchin B, Glastre C, Fouilhoux A, Canterino I, David L. [Neurologic signs revealing a Behçet's disease: two pediatric case reports]. Arch Pediatr 2002; 9 (11) 1160-1162
• 125 Kara B, Somer A, Pişkin S, Aydinli N, Salman N, Yalçin I. Neuro-Behçet syndrome presenting as acute meningeal syndrome. J Infect 2006; 52 (04) e120-e123
• 126 Iwańczak B, Reich A, Kofla-Dłubacz A, Kazanowska B, Ruczka M. Neurologic appearence of Behçet disease in 14-year old boy treated with adalimumab with good result [in Polish]. Pol Merkuriusz Lek 2016; 40 (236) 110-112
• 127 Hacihamdioglu DO, Demiriz M, Sobaci G, Kocaoglu M, Demirkaya E, Gok F. Cerebral vein thrombosis in a four year old with Behçet's disease. Reumatol Clin 2014; 10 (04) 254-256
• 128 Ozen S, Bilginer Y, Besbas N, Ayaz NA, Bakkaloglu A. Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 2010; 169 (04) 427-430
• 129 Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int 2013; 33 (12) 3105-3108
• 130 Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 1998; 159 (02) 181-185
• 131 Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behçet's syndrome. J Neurol Sci 2008; 272 (1–2): 99-105
• 132 Mathew AJ, Goel R, Kumar S, Danda D. Childhood-onset Takayasu arteritis: an update. Int J Rheum Dis 2016; 19 (02) 116-126
• 133 Millar AJ, Gilbert RD, Brown RA, Immelman EJ, Burkimsher DA, Cywes S. Abdominal aortic aneurysms in children. J Pediatr Surg 1996; 31 (12) 1624-1628
• 134 Karande S, Jagtap S, Joshi A. Posterior reversible encephalopathy syndrome revealing Takayasu's arteritis. Indian J Pediatr 2009; 76 (02) 218-220
• 135 Jain S, Sharma N, Singh S, Bali HK, Kumar L, Sharma BK. Takayasu arteritis in children and young indians. Int J Cardiol 2000; 75 (Suppl. 01) S153-S157
• 136 Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. Int J Cardiol 1998; 66 (01) (Suppl. 01) S85-S90 , discussion S91
• 137 del Brutto OH, Lara-Terán J, Sánchez J, Lara-Montiel J. Cerebrovascular complications of Takayasu's disease [in Spanish]. Rev Neurol 1996; 24 (131) 803-805
• 138 Weiner SM, Vaith P, Walker UA, Brink I. Detection of alterations in brain glucose metabolism by positron emission tomography in Takayasu's arteritis. Eur J Nucl Med Mol Imaging 2004; 31 (02) 300-302
• 139 Fujita M, Komatsu K, Hatachi S, Yagita M. Reversible posterior leukoencephalopathy syndrome in a patient with Takayasu arteritis. Mod Rheumatol 2008; 18 (06) 623-629
• 140 Pfefferkorn T, Bitterling H, Hüfner K. , et al. Malignant hemispheric infarction in Takayasu arteritis. J Neurol 2008; 255 (09) 1425-1426
• 141 Edwards KK, Lindsley HB, Lai CW, Van Veldhuizen PJ. Takayasu arteritis presenting as retinal and vertebrobasilar ischemia. J Rheumatol 1989; 16 (07) 1000-1002
• 142 Ozen S, Duzova A, Bakkaloglu A. , et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr 2007; 150 (01) 72-76
• 143 Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 2010; 29 (03) 329-332
• 144 Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 ‘difficult-to-treat’ cases of Takayasu arteritis. Int J Rheum Dis 2013; 16 (06) 754-761
• 145 Comarmond C, Plaisier E, Dahan K. , et al. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 2012; 11 (09) 678-684
• 146 Robbs JV, Human RR, Rajaruthnam P. Operative treatment of nonspecific aortoarteritis (Takayasu's arteritis). J Vasc Surg 1986; 3 (04) 605-616
• 147 Sugawara Y, Orihashi K, Okada K, Kochi K, Imai K, Sueda T. Surgical treatment of aortic coarctation associated with multi-vessel brachiocephalic involvement in takayasu's arteritis. Ann Thorac Cardiovasc Surg 2003; 9 (03) 202-205
• 148 Davidovic L, Sindjelic R, Jovanovic Z, Bozic V, Markovic D. Takayasu's aortoarteritis. Acta Chir Iugosl 2005; 52 (03) 95-98
• 149 Kanda M, Shinoda S, Masuzawa T. Ruptured vertebral artery-posterior inferior cerebellar artery aneurysm associated with pulseless disease—case report. Neurol Med Chir (Tokyo) 2004; 44 (07) 363-367
• 150 Nölle B, Specks U, Lüdemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989; 111 (01) 28-40
• 151 Sun L, Wang H, Jiang X. , et al. Clinical and pathological features of microscopic polyangiitis in 20 children. J Rheumatol 2014; 41 (08) 1712-1719
• 152 Rottem M, Fauci AS, Hallahan CW. , et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr 1993; 122 (01) 26-31
• 153 Bhadu D, Kumar P, Malhotra KP, Sharma A, Sharma M, Srivastava D. Central nervous system vasculitis in pediatric microscopic polyangiitis. Acta Reumatol Port 2016; 41 (04) 372-375
• 154 Taylor CT, Buring SM, Taylor KH. Treatment of Wegener's granulomatosis with immune globulin: CNS involvement in an adolescent female. Ann Pharmacother 1999; 33 (10) 1055-1059
• 155 Drachman DA. Neurological complications of Wegener's granulomatosis. Arch Neurol 1963; 8 (02) 145-155
• 156 Kara O, Demirel F, Acar BC, Cakar N. Wegener granulomatosis as an uncommon cause of panhypopituitarism in childhood. J Pediatr Endocrinol Metab 2013; 26 (9–10): 959-962
• 157 Iglesias E, Eleftheriou D, Mankad K, Prabhakar P, Brogan PA. Microscopic polyangiitis presenting with hemorrhagic stroke. J Child Neurol 2014; 29 (08) NP1-NP4
• 158 Tan J, Hussain A, Daiwajna R, Chai LK, Lim E, Han A. Microscopic polyangiitis complicated by intracerebral hemorrhage and pulmonary hemorrhage in a pediatric patient. Am J Case Rep 2013; 14: 276-279
• 159 Kok J, Bosseray A, Brion JP, Micoud M, Besson G. Chorea in a child with Churg–Strauss syndrome. Stroke 1993; 24 (08) 1263-1264
• 160 Cury DB. Arnold S, Payne B. Allergic granulomatous angiitis associated with uveoscleritis and papilledema. AMA Arch Opthalmol 1956; 55 (02) 261-266
• 161 Suresh E. Diagnostic approach to patients with suspected vasculitis. Postgrad Med J 2006; 82: 483-488
• 162 Stone JH, Talor M, Stebbing J. , et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000; 13 (06) 424-434
• 163 Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 2014; 10 (08) 494-501
• 164 Houben E, Bax WA, van Dam B. , et al. Diagnosing ANCA-associated vasculitis in ANCA positive patients: a retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine (Baltimore) 2016; 95 (40) e5096 . doi: 10.1097/MD.0000000000005096
• 165 Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am 1995; 21 (04) 911-947
• 166 Iudici M, Quartier P, Terrier B, Mouthon L, Guillevin L, Puéchal X. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet J Rare Dis 2016; 11 (01) 141 . Doi: 10.1186/s13023-016-0523-y
• 167 Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009; 27 (01) (Suppl. 52) S65-S69
• 168 Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol 2005; 11 (06) 314-318
• 169 Soriano A, Lo Vullo M, Casale M, Quattrocchi CC, Afeltra A. Meningeal involvement in Wegener granulomatosis: case report and review of the literature. Int J Immunopathol Pharmacol 2012; 25 (04) 1137-1141
• 170 Guillevin L, Lhote F, Cohen P. , et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg–Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38 (11) 1638-1645
• 171 Topaloglu R, Besbas N, Saatci U, Bakkaloglu A, Oner A. Cranial nerve involvement in childhood polyarteritis nodosa. Clin Neurol Neurosurg 1992; 94 (01) 11-13
• 172 Ragge NK, Harris CM, Dillon MJ, Chong WK, Elston J, Taylor DS. Ocular tilt reaction due to a mesencephalic lesion in juvenile polyarteritis nodosa. Am J Ophthalmol 2003; 135 (02) 249-251
• 173 Morfín-Maciel B, Medina A, Espinosa Rosales F, Berrón R, Huerta López J. Central nervous system involvement in a child with polyarteritis nodosa and severe atopic dermatitis. Rev Alerg Mex 2002; 49 (06) 189-195
• 174 Altinok D, Yildiz YT, Ruşen E, Eryilmaz M, Tacal T. Central nervous system involvement of polyarteritis nodosa: a case report. Turk J Pediatr 2001; 43 (02) 146-150
• 175 Deshpande PV, Gilbert R, Alton H, Milford DV. Microscopic polyarteritis with renal and cerebral involvement. Pediatr Nephrol 2000; 15 (1–2): 134-135
• 176 Wahezi DM, Gomes WA, Ilowite NT. Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment. Pediatrics 2010; 126 (03) e719-e722
• 177 Paula De Carvalho Panzeri Carlotti A, Paes Leme Ferriani V, Tanuri Caldas C. , et al. Polyarteritis nodosa with central nervous system involvement mimicking meningoencephalitis. Pediatr Crit Care Med 2004; 5 (03) 286-288
• 178 Guirola R, Hunter JV, Perez M, Muscal E. Childhood polyarteritis nodosa presenting with central nervous system manifestations and the posterior reversible encephalopathy syndrome. J Child Neurol 2014; 29 (01) 103-107
• 179 Toyoda K, Tsutsumi K, Hirao T. , et al. Ruptured intracranial aneurysms in pediatric polyarteritis nodosa: case report. Neurol Med Chir (Tokyo) 2012; 52 (12) 928-932
• 180 Guillevin L, Cevallos R, Durand-Gasselin B, Lhote F, Jarrousse B, Callard P. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997; 148 (03) 198-204
• 181 Hersh AO, von Scheven E, Yazdany J. , et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009; 61 (01) 13-20
• 182 Fraison JB, Sève P, Dauphin C. , et al; CRI and the French Vasculitis Study Group. Kawasaki disease in adults: Observations in France and literature review. Autoimmun Rev 2016; 15 (03) 242-249
• 183 Noel N, Bernard R, Wechsler B. , et al. Long-term outcome of neuro-Behçet's disease. Arthritis Rheumatol 2014; 66 (05) 1306-1314
• 184 Pagnoux C, Seror R, Henegar C. , et al; French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62 (02) 616-626